✦ LIBER ✦

Summary of guideline for the treatment of bipolar disorder

✍ Scribed by Philip B. Mitchell; Gin S. Malhi; Bernette L. Redwood; Jillian Ball

Publisher: Informa plc
Year: 2003
Tongue: English
Weight: 182 KB
Volume: 11
Category: Article
ISSN: 1039-8562
DOI: 10.1046/j.1440-1665.2003.00520.x

No coin nor oath required. For personal study only.

✦ Synopsis

The past decade has witnessed an extraordinary expansion of treatments available for bipolar disorder. Ten years ago, lithium was the only approved agent for this condition. Since that time, carbamazepine, valproate and olanzapine have received regulatory approval for the acute treatment of mania. Concurrently, randomized controlled trials of various psychological interventions have been recently reported, respecting the important psychological effects of this condition. The present summary provides recommended treatment guidelines for each phase of this condition: mania, mixed episodes, depression and long-term prophylaxis. Levels of evidence for specific treatments are provided and placed in the context of overall principles of quality clinical management.

📜 SIMILAR VOLUMES

Summary of guideline for the treatment o

Summary of guideline for the treatment of panic disorder and agoraphobia

✍ Gavin Andrews; Mark Oakley-Browne; David Castle; Fiona Judd; Andrew Baillie 📂 Article 📅 2003 🏛 Informa plc 🌐 English ⚖ 119 KB

Objective: To provide a summary of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Clinical Practice Guideline for the treatment of panic disorder and agoraphobia Conclusions: Evidence-based treatments for panic disorder and agoraphobia are now clear. These conditions are c

Summary of guideline for the treatment o

Summary of guideline for the treatment of depression

✍ Pete M. Ellis; Ian B. Hickie; Don A. R. Smith 📂 Article 📅 2003 🏛 Informa plc 🌐 English ⚖ 120 KB

Depression is common, serious and treatable. The Australian and New Zealand Clinical Practice Guideline for the Treatment of Depression by Specialist Services provides evidence-based treatment guidance across the spectrum of depressive disorders and delineates where specialist treatment and primary

Divalproex for the treatment of geriatri

Divalproex for the treatment of geriatric bipolar disorder

✍ Donald J. Mordecai; Javaid I. Sheikh; Ira D. Glick 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 2 views

Divalproex is now commonly used to treat bipolar disorder in older patients. However, it has yet to be systematically studied in this population. This report describes six older bipolar patients treated with divalproex. Of the six, ®ve showed some improvement with divalproex alone or in combination

Genetic analysis of bipolar disorder: Su

Genetic analysis of bipolar disorder: Summary of GAW10

✍ John Rice 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

Participants in the Bipolar Disorder component of Genetic Analysis Workshop 10 had access to five distributed data sets containing chromosome 18 marker data and five data sets containing chromosome 5 data. A total of 25 groups participated in analyses and applied a myriad of methodologically innovat

Treatment of bipolar disorder in older a

Treatment of bipolar disorder in older adults

✍ Martha Sajatovic 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract ## Background It has been reported that 10% of all patients with bipolar disorder develop their illness after the age of 50, with bipolar disorder accounting for 5–19% of mood disorder presentations in the elderly. There has been a growing awareness regarding the manifestation of bipol

Development of the treatment attitudes q

Development of the treatment attitudes questionnaire in bipolar disorder

✍ Sheri L. Johnson; Daniel Fulford 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

## Abstract Despite the success of pharmacotherapy in the management of bipolar disorder, as many as one‐half of those in treatment discontinue their medication over time. Currently, no self‐report measure is available that predicts treatment engagement in bipolar disorder. The goal of the current